Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
This study is currently recruiting participants.
Study NCT00352885 Information provided by National Institute of Mental Health (NIMH)
First Received: July 13, 2006 Last Updated: March 17, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Depression
Additional conditions recognized in this trial
Depressive Disorder
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Interventions listed in this trial
Escitalopram
Placebo
IL-2
Additional drug interventions recognized in this trial
Citalopram
Dexetimide
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antineoplastic Agents
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Institute of Mental Health (NIMH)
Back to top of Main Content
